###begin article-title 0
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival
###end article-title 0
###begin p 1
###xml 29 49 29 49 <email xmlns:xlink="http://www.w3.org/1999/xlink">Manfred.Kopf@ethz.ch</email>
CORRESPONDENCE Manfred Kopf: Manfred.Kopf@ethz.ch
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 848 849 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Granulocyte macrophage-colony stimulating factor (GM-CSF) is critically involved in development of organ-related autoimmune inflammatory diseases including experimental allergic encephalitis and collagen-induced arthritis. Roles of GM-CSF in the initiation and in the effector phase of the autoimmune response have been proposed. Our study was designed to investigate the mechanisms of GM-CSF in autoimmunity using a model of autoimmune heart inflammatory disease (myocarditis). The pathological sequel after immunization with heart myosin has been shown previously to depend on IL-1, IL-6, IL-23, and IL-17. We found that innate GM-CSF was critical for IL-6 and IL-23 responses by dendritic cells and generation of pathological Th17 cells in vivo. Moreover, GM-CSF promoted autoimmunity by enhancing IL-6-dependent survival of antigen specific CD4+ T cells. These results suggest a novel role for GM-CSF in promoting generation and maintenance of Th17 cells by regulation of IL-6 and IL-23 in vivo.
###end p 3
###begin p 4
Abbreviations used: EAE, experimental allergic encephalitis; EAM, experimental autoimmune myocarditis; GM-CSF, granulocyte macrophage-colony stimulating factor; myhcalpha, myosin heavy chain alpha; PAMP, Pathogen associated molecular pattern; PI, propidium iodide; TLR, toll-like receptor.
###end p 4
###begin p 5
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1091 1092 1083 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 1094 1095 1086 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1109 1110 1101 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1333 1334 1322 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1344 1345 1333 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1346 1348 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1450 1452 1439 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1515 1516 1501 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1518 1520 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1561 1563 1543 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1653 1655 1635 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1668 1670 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
Recent studies demonstrated a novel proinflammatory subpopulation of IL-17- producing T helper cells, termed Th17, that are distinct from Th1 and Th2. These Th17 cells have been suggested to mediate inflammation associated with several organ-related autoimmune diseases including experimental allergic encephalitis (EAE) (1-3), collagen-induced arthritis (4), and experimental autoimmune myocarditis (EAM) (5, 6). Evidence supporting a new concept in which IL-23-dependent Th17, and not IL-12-dependent Th1, cells are responsible for autoimmune inflammation came from reports showing that IL-12 (p35)-deficient and IFN-gamma-deficient mice developed normal or even exaggerated autoimmune inflammation, whereas IL-23 (p19)-deficient and IL-17-deficient mice were protected. Consequently, there has been a strong interest in defining effector cytokines produced by the pathological Th17 cells and the conditions and factors determining development and activity of Th17 cells. Besides IL-17A and IL-17F, Th17 cells have been reported to coexpress the proinflammatory cytokines IL-6, TNF-alpha (2, 7), and IL-22 (8). Similar to Th1 and Th2 development, the cytokine environment plays a critical role in positive and negative regulation of Th17 development. TGF-beta, IL-6, and IL-1 have been shown to induce IL-17 production in naive CD4+ T cells (9-12), whereas IL-23 turned out to be essential for expansion and survival of Th17 effector memory cells (11). IL-6 plays a key role as it inhibits TGF-beta-induced Treg (9, 13) differentiation and induces RORgammat (14), a transcription factor specifically required for Th17 development. In contrast, IL-27 (15) and IL-25 (16) have been shown to negatively regulate Th17 development.
###end p 5
###begin p 6
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 444 446 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 447 449 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 467 470 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 633 635 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 669 672 665 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 812 814 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 816 818 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 995 997 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 999 1001 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1319 1321 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
Granulocyte macrophage-colony stimulating factor (GM-CSF) is secreted in response to inflammatory stimuli such as LPS, IL-1, and TNF-alpha by a variety of different cells, including endothelium, fibroblasts, muscle cells, and macrophages, and by activated T cells (for review see reference 17). It was first described as a hematopoietic cytokine promoting proliferation and differentiation of macrophages, granulocytes, and DC from precursors (18-20). However, GM-CSF-/- mice showed normal development of myeloid cells, including macrophages and DC, except a defect of alveolar macrophage function resulting in alveolar proteinosis (21). In contrast, analysis of GM-CSF-/- mice demonstrated an essential role of GM-CSF for development of autoimmune inflammatory diseases such EAE and collagen-induced arthritis (22, 23). In addition, anti-GM-CSF therapy from time of immunization or from first signs of clinical disease completely prevented or ameliorated autoimmune inflammation, respectively (23, 24). It has been proposed that GM-CSF promotes T cell proliferation and pathological Th1 responses indirectly by activation of macrophages, DC, and microglia cells in the initiation or the effector phase and possibly the generation of chemoattractant gradients for recruitment of inflammatory cells to the target organ (23). However, the precise mechanisms have remained elusive.
###end p 6
###begin p 7
###xml 412 419 392 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 559 560 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 562 564 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 566 568 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 636 638 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 640 642 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 435 438 <span type="species:ncbi:31658">CFA</span>
In this study, we have determined the mechanism of action of GM-CSF in development of EAM, an animal model of human dilated cardiomyopathy, the most common form of cardiomyopathy (approximately80-90% of cases) for which mortality rates remain unacceptably high. EAM is induced by immunization of susceptible mice with cardiac myosin or a peptide located in the head portion of myosin heavy chain alpha (myhcalpha614-629) emulsified in CFA. Previous reports have demonstrated that the cytokines IL-6, IL-1, IL-23, and IL-17 are crucial for development of EAM (5, 25, 26), whereas IFN-gamma is a negative regulator of heart inflammation (27, 28). Thus, the cytokine network responsible for pathological inflammation in the heart (EAM) and brain (EAE) appears to be very similar.
###end p 7
###begin p 8
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
We found that GM-CSF was essential to inhibit apoptosis and promote IL-17 production by autoimmune CD4+ T cells. Both activities are not mutually exclusive and can be mediated by IL-6. In fact, we found that GM-CSF was essential for IL-6 and IL-23 production by DC and/or macrophages in the initiation phase of the autoimmune response
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
GM-CSF-/- mice are protected from autoimmune myocarditis
###end title 10
###begin p 11
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 156 163 152 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 363 366 359 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 472 487 468 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 535 538 531 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 168 171 <span type="species:ncbi:31658">CFA</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
To investigate the role of GM-CSF in autoimmune myocarditis, we immunized GM-CSF-/- mice and BALB/c controls with a peptide derived from the myhc (myhcalpha614-629) in CFA on day 0 and boosted on day 7. By day 21, WT mice developed severe cardiac inflammatory lesions, characterized by infiltrates of lymphocytes, histiocytes, and neutrophils. In contrast, GM-CSF-/- mice showed strongly reduced disease prevalence and histological score because of few inflammatory foci (Fig. 1, A and B). The few lesions found in the hearts of GM-CSF-/- mice had a similar cellular composition as the inflammatory infiltrates of WT hearts (unpublished data).
###end p 11
###begin p 12
###xml 0 118 0 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduced autoimmune myocarditis, T cell proliferation, and antibody responses to heart myosin in GM-CSF&#8211;deficient mice.</bold>
###xml 125 128 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 218 225 214 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 470 473 466 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 549 550 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 684 691 676 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 723 724 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 801 808 789 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 237 240 <span type="species:ncbi:31658">CFA</span>
Reduced autoimmune myocarditis, T cell proliferation, and antibody responses to heart myosin in GM-CSF-deficient mice. GM-CSF-/- (open circles) and WT (closed circles) mice were immunized at days 0 and 7 with myhcalpha614-629 peptide in CFA. Hearts were removed at day 21 and fixed in 4% formalin. (A) The severity of inflammatory infiltrates was scored as described in Materials and methods. (B) Representative images of Hematoxylin and Eosin stainings of WT and GM-CSF-/- heart sections. Bars: (left) 2 mm; (middle) 0.5 mm; (right) 0.1 mm. (C) CD4+ T cells were isolated from the spleen 21 d after immunization and in vitro restimulated with BM-DC and titrating amounts of myhcalpha614-629. Proliferation was assessed by 3H-thymidine incorporation after 3 d of culture. (D) Serum titers of myhcalpha614-629-specific IgM and IgG at day 21 d after immunization measured by ELISA. Horizontal lines represent the mean titer for each group (D) and the median histological scores of groups (A). Data shown are representative of three to four experiments. *, P < 0.05.
###end p 12
###begin p 13
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 198 205 194 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 255 263 251 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 274 281 266 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 294 295 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 351 352 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 372 375 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 428 431 420 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 531 538 519 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 598 606 586 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 728 729 716 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
EAM is a CD4 T cell-mediated disease (29). To assess activation and function of myosin-specific CD4+ T cells, we purified splenic CD4+ T cells from immunized mice and stimulated these with myhcalpha614-629 presented by WT primary DC in vitro. As shown in Fig. 1 C, myhcalpha614-629-specific CD4+ T cells from WT mice proliferated potently, whereas CD4+ T cells from GM-CSF-/- mice failed to proliferate ex vivo. Moreover, GM-CSF-/- mice mounted strongly reduced CD4 T helper cell-dependent IgG antibody responses, whereas myhcalpha614-629-specific IgM antibody level was comparable to WT controls (Fig. 1 D). Thus, our results suggest that GM-CSF is critical for development of autoimmune myocarditis by promoting autoimmune CD4+ T cell responses.
###end p 13
###begin title 14
GM-CSF enhances secretion of proinflammatory cytokines by DC
###end title 14
###begin p 15
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
DC are the key cells for priming T cells in vivo (30). It is known that different stages of maturation have different effects on immune responses (31). Immature (or semimature) DC have been shown to induce T cell anergy or tolerance (32), whereas combined toll-like receptor (TLR) and CD40 stimulation of mature DC can break tolerance and induce autoimmune disease (33).
###end p 15
###begin p 16
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 232 240 232 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 346 349 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 407 415 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 690 693 682 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 700 715 692 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 785 793 777 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
Primary DC from spleens of WT and GM-CSF-/- mice showed comparable surface expression of the maturation markers MHC class II, CD40, and CD86 before and after stimulation with CpG or LPS, the ligands for TLR9 and TLR4, respectively (Fig. 2 A). Moreover, production of the proinflammatory cytokines IL-6, IL-12, and TNF-alpha by DC of WT and GM-CSF-/- mice was comparably increased upon stimulation with CpG (Fig. 2 B) or LPS (not depicted). In contrast, WT DC did not produce detectable GM-CSF (unpublished data). Addition of recombinant GM-CSF significantly augmented production of IL-6, IL-12, and TNF-alpha, and transcription of IL-23p19 by CpG stimulated primary DC of both WT and GM-CSF-/- mice (Fig. 2, B and C) but had no effect on up-regulation of MHC class II, CD40, and CD86 (Fig. 2 A). These results suggest that GM-CSF produced by non-DC can augment production of proinflammatory cytokines by DC during an immune response but that it is not required for homeostatic DC development or up-regulation of classical DC maturation/activation markers.
###end p 16
###begin p 17
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GM-CSF enhances TLR-induced production of proinflammatory cytokines by DC.</bold>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 354 357 352 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 383 386 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
GM-CSF enhances TLR-induced production of proinflammatory cytokines by DC. DC isolated from spleens of naive WT and GM-CSF-/- mice were stimulated with 1 muM CpG or 1 mug/ml LPS in vitro. (A) Surface expression of CD86, CD40, and MHC class II was assessed by flow cytometry after 6 h. Unstimulated cells (shaded curve), stimulated WT (solid line), GM-CSF-/- (dashed line), and GM-CSF-/- DC in the presence of 20 ng/ml rGM-CSF (dotted line). (B) ELISA measurement of IL-6, IL-12(p40/p70), and TNF-alpha in supernatants of DC stimulated for 24 h with CpG in the presence and absence of 20 ng/ml GM-CSF. (C) IL-23p19 measured by quantitative PCR of DC stimulated for 4 h with 1 muM CpG in the presence and absence of GM-CSF. One representative experiment of at least two is shown. Error bars indicate SD.
###end p 17
###begin title 18
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Reduced IL-6 production by DC in GM-CSF-/- mice
###end title 18
###begin p 19
###xml 70 77 66 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 105 108 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 410 418 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 768 771 752 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 806 814 790 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 838 839 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 862 863 846 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 868 869 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 879 880 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 885 886 869 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1020 1023 1004 1007 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1030 1038 1014 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1103 1106 1087 1090 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1263 1264 1247 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1283 1286 1267 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1312 1320 1296 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1398 1399 1382 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1620 1623 1604 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1904 1910 1888 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 78 81 <span type="species:ncbi:31658">CFA</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1107 1111 <span type="species:ncbi:10090">mice</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1624 1628 <span type="species:ncbi:10090">mice</span>
###xml 1792 1795 <span type="species:ncbi:31658">CFA</span>
To assess cytokine production by antigen-presenting cells in myhcalpha614-629/CFA-immunized WT and GM-CSF-/- mice, we purified a gemisch of cells expressing CD11b and/or CD11c, including macrophages and DC (Mac/DC), from spleens at various time points after immunization and cultured them in the absence or presence of agonist anti-CD40 mAb to mimic stimulation by activated T cells through CD40L. As shown in Fig. 3 A, Mac/DC from WT mice produced IL-6 from day 2 peaking at day 7 after immunization, which was two- to threefold enhanced by CD40 stimulation. In contrast, IL-6 production by Mac/DC from KO was markedly impaired without and with CD40 stimulation. IL-6 expression in vivo determined by real time PCR was approximately10-fold reduced in Mac/DC of GM-CSF-/- mice at day 7 after innoculation (Fig. 3 B). Purification of CD11c+ cells, including CD11c+CD11b- and CD11c+CD11b+ DC, were a source of IL-6, IL-23, and IL-12/23p40 in immunized WT mice. Both IL-6 and IL-23 production was impaired in DC from GM-CSF-/- mice (Fig. 3 C). To exclude impaired maturation of DC and macrophages in GM-CSF-/- mice, we measured expression of typical maturation markers directly ex vivo. We found comparable MHC class II, CD80, CD86, and CD40 on cell surface of CD11c+DC in WT and GM-CSF-/- mice isolated at days 4 (Fig. 3 D) and 7 (not depicted) after immunization. Similarly, macrophages (i.e., CD11b+cells) did not show a difference in these surface molecules, although their expression was expectedly weaker than on DC (unpublished data). Comparable expression of CD40 rules out reduced stimulation of Mac/DC from GM-CSF-/- mice by agonistic CD40 mAb. These data demonstrate that GM-CSF is essential for IL-6 and IL-23 production by DC in vivo in response to immunization with autoantigen in CFA and confirm the data showing that exogenous GM-CSF enhances IL-6 and IL-23 production by CpG-stimulated DC (Fig. 2).
###end p 19
###begin p 20
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduced production of IL-6 in immunized GM-CSF<sup>&#8722;/&#8722;</sup> mice.</bold>
###xml 69 72 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 112 119 108 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 144 150 140 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 192 193 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 204 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 481 482 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 509 510 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 621 622 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 873 874 866 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 952 955 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1055 1058 1048 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1100 1107 1088 1095 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 1207 1210 1193 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 120 123 <span type="species:ncbi:31658">CFA</span>
###xml 956 960 <span type="species:ncbi:10090">mice</span>
###xml 1015 1019 <span type="species:ncbi:10090">mice</span>
###xml 1059 1063 <span type="species:ncbi:10090">mice</span>
###xml 1211 1215 <span type="species:ncbi:10090">mice</span>
###xml 1449 1453 <span type="species:ncbi:10090">mice</span>
###xml 1555 1559 <span type="species:ncbi:10090">mice</span>
Reduced production of IL-6 in immunized GM-CSF-/- mice. WT and GM-CSF-/- mice were immunized s.c. with myhcalpha614-629/CFA as described in the Fig. 1 legend. (A) At the times indicated, CD11b+ and CD11c+ cells were isolated by magnetic sorting and cultured in the presence and absence of anti-CD40 for 20 h. IL-6 concentrations in the supernatant was measured by ELISA. (B) Expression of IL-6 relative to beta-actin was assessed by quantitative PCR using cDNA generated from CD11b+ cells. (C) At day 7, CD11c+ cells were isolated by magnetic sorting and cultured in the presence and absence of anti-CD40 for 24 h (4 x 105 DC per well). IL-6, IL-23, and IL-12p40 levels in the supernatant were measured by ELISA. (D) Analysis of draining LN cells by flow cytometry at day 4 after immunization. Histograms show expression of CD80, CD86, CD40, and MHC class II gated on CD11c+ cells. Continuous and dotted lines represent cells of immunized WT and GM-CSF-/- mice, respectively. Shaded curves represent cells of naive mice. (E) BM-derived DC of WT and GM-CSF-/- mice were pulsed with 10 mug/ml myhcalpha614-629 and stimulated with 1 mug/ml LPS and 5 mug/ml anti-CD40 for 4 h before injection into WT and GM-CSF-/- mice at days 0, 2, and 4. At day 10, hearts were removed and myocarditis scored by histology. Horizontal lines indicate median. Error bars in A indicate SD of triplicate culture wells. Cells were isolated from pooled draining LN of three mice per time point. Error bars in C indicate SD of triplicate cultures of draining LN DC of four to five mice per time point. Data shown are representative of at least two experiments. *, P < 0.05.
###end p 20
###begin title 21
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Activated DC induce mild myocarditis in GM-CSF-/- mice
###end title 21
###begin p 22
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 206 213 202 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 303 306 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 331 339 327 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 359 362 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 524 527 520 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 750 753 746 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 852 860 848 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 990 993 986 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1056 1073 1052 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Figs. 2 (B and C)</xref>
###xml 1078 1085 1074 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">3 (A&#8211;C)</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
We next asked whether LPS/CD40 activation of BM-DC grown in the presence of recombinant GM-CSF could restore disease in GM-CSF-/- mice. To this end, BM-DC of WT and GM-CSF-/- mice were loaded with myhcalpha614-629 and activated with LPS and anti-CD40 mAb before adoptive transfer into both WT and GM-CSF-/- recipients. As shown in Fig. 3 E, both WT and GM-CSF-/- DC induced comparably strong heart inflammation in WT mice confirming the ability of TLR/CD40-activated DC to induce myocarditis and suggesting that DC of GM-CSF-/- mice have no intrinsic defect in proinflammatory cytokine production when grown in exogenous GM-CSF. Interestingly, injection of GM-CSF-derived BM-DC activated with LPS/CD40 partially restored disease development in GM-CSF-/- mice, although the disease score was still significantly reduced compared with WT recipient mice (Fig. 3 E). These results show that BM-DC grown and activated with a combination of GM-CSF, LPS, and CD40 induce mild myocarditis in GM-CSF-/- mice, probably by secretion of IL-6 and IL-23 as indicated in Figs. 2 (B and C) and 3 (A-C). In addition, the data indicate that such activated DC trigger GM-CSF production by other cells, which are key for development of severe myocarditis.
###end p 22
###begin title 23
T cell proliferation and differentiation of Th17 cells, but not Th1 and Th2 cells, is impaired in GM-CSF-deficient CD4 T cells in vitro
###end title 23
###begin p 24
###xml 21 29 21 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 271 264 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 296 299 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 380 383 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 425 428 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 735 743 735 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 822 825 822 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 829 830 829 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 890 893 890 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 961 969 961 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 1274 1275 1270 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1290 1291 1286 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1331 1332 1327 1328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1441 1442 1437 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1453 1461 1449 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 234 249 <span type="species:ncbi:10090">transgenic mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 900 904 <span type="species:ncbi:10090">mice</span>
The results shown in Fig. 1 C suggest that GM-CSF is required for activation, differentiation, expansion, and/or survival of autoimmune CD4+ T cells. To experimentally address these possibilities, we capitalized from crossing DO11.10 transgenic mice expressing OVA323-339-specific TCR with GM-CSF-/- mice. Naive (i.e., CD62Lhi) DO11.10 transgenic T cells were isolated from GM-CSF-/- and WT mice and cultured with both GM-CSF-/- and WT splenic DC in the presence of titrated concentrations of specific antigen to measure T cell activation, proliferation, and Th1/Th2 polarization at days 3 and 5, respectively. T cell activation, measured by up-regulation of CD25 and down-regulation of CD62L, was unaffected in the absence of GM-CSF (Fig. 4 A). In contrast, T cell proliferation was impaired in cultures containing GM-CSF-/- CD4+ T cells, independent of whether DC were derived from GM-CSF-/- or WT mice, and it was reconstituted by adding recombinant GM-CSF (Fig. 4 B). For unknown reasons, a commercially available GM-CSF-blocking antibody failed to inhibit T cell proliferation in this experimental setup. Th1 and Th2 cell differentiation was induced by culturing cells with high and low dose antigen, respectively, as reported previously (34). A proportion of IFN-gamma+ (Th1) and IL-4+ (Th2) cells coproduced GM-CSF in WT CD4+ T cells (unpublished data). However, Th1 and Th2 differentiation remained unaffected in GM-CSF-deficient CD4+ T cells. (Fig. 4 C).
###end p 24
###begin p 25
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GM-CSF production by CD4<sup>+</sup> T cells promotes proliferation and differentiation of Th17, but not Th1 or Th2, cells in vitro.</bold>
###xml 131 138 131 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 227 230 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 386 393 386 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 410 411 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 558 559 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 823 830 818 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 900 901 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 980 983 970 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 987 988 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1084 1085 1074 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
GM-CSF production by CD4+ T cells promotes proliferation and differentiation of Th17, but not Th1 or Th2, cells in vitro. Naive OVA323-339 TCR transgenic CD4+ T cells purified from spleens of DO11.10/GM-CSF-/- or DO11.10/GM-CSF+/+ mice were cocultured with splenic DC purified from GM-CSF-deficient (KO) or WT mice in the presence of indicated concentrations of ovalbumin protein or OVA323-339 peptide. (A) CD4+ T cell activation measured by CD25 and CD62L surface expression after 3 d of culture. (B) CD4 T cell proliferation measured by pulsing cells with 3H-Thymidine for the last 12 h of a 60-h coculture. (C) Th1/Th2 cell differentiation driven by indicated antigen concentrations was determined by intracellular staining of IFN-gamma and IL-4 after 5 d of coculture. (D and E) Cocultures were stimulated by 10 muM OVA323-339 and 1 muM CpG for 4 d. IL-17, IFN-gamma, and GM-CSF production by CD4+ T cells was determined by intracellular staining in cultures containing GM-CSF+/+ CD4+ T cells and DC (D) or indicated combinations of WT and KO T cells and DC (E). (F) WT and KO CD4+ T cells and DC were cultured with anti-CD3 in Th17-polarizing conditions including 5 ng/ml TGFbeta1, 20 ng/ml IL-6, 20 ng/ml IL-21, 1 muM CpG, and 100 mug/ml curdlan. Cytokine production was determined by intracellular staining at day 4.
###end p 25
###begin p 26
###xml 126 127 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 129 131 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 475 478 472 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 490 491 487 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 525 528 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 585 586 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 694 702 687 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 787 788 780 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 815 823 808 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 849 850 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1152 1160 1139 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 1248 1249 1235 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1259 1267 1246 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 1418 1419 1399 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1429 1437 1410 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
Th17 cell differentiation in vitro can be induced by TCR stimulation in the presence of TGF-beta together with IL-6 or IL-21 (9, 11). In addition, exposure of DC to microbial products, such as CpG and Curdlan, drives Th17 polarization by stimulation of IL-6 and other inflammatory cytokines (i.e., IL-1 and IL-23), which may reflect the more physiological situation. To assess the role of GM-CSF in Th17 polarization in vitro, we performed four-way cocultures of WT or GM-CSF-/- DC with CD4+ T cells from DO11.10 WT or GM-CSF-/- mice and specific antigen in the presence of CpG. WT CD4+ T cells grown in this condition differentiated into populations secreting GM-CSF, IL-17, and/or IFN-gamma (Fig. 4 D). Th17 cell differentiation was impaired in cultures containing GM-CSF-deficient CD4+ T cells with KO or WT DC (Fig. 4 E). Furthermore, DC and CD4+ T cells from WT and KO mice were cultured with anti-CD3 in the presence of cytokines (i.e., IL-6/TGF-beta and IL-21/TGF-beta) or Pathogen associated molecular patterns (PAMPs; i.e., CpG and Curdlan) known to promote Th17 differentiation. Confirming data obtained in antigen-specific cultures shown in Fig. 4 E, Th17 polarization induced by CpG and Curdlan was dependent on GM-CSF production by CD4+ T cells (Fig. 4 F). In contrast, Th17 development induced by exogenous IL-6/TGF-beta or IL-21/TGF-beta was comparable in cultures containing GM-CSF-deficient and WT CD4+ T cells (Fig. 4 F), suggesting that exogenous IL-6 (or IL-21) overcomes GM-CSF requirement. Notably, DC/CD4 stimulation cultures grown with exogenous GM-CSF together with TGF-beta in the absence of IL-6 did not induce Th17 differentiation (unpublished data), indicating that microbial stimulation of the DC is critical.
###end p 26
###begin p 27
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Collectively, these data suggest that DC produce proinflammatory cytokines, including IL-6 but not GM-CSF, upon microbial stimulation with PAMPs. This promotes GM-CSF production by CD4+ T cells, which acts back on DC to further enhance IL-6-production resulting in Th17 differentiation and proliferation.
###end p 27
###begin title 28
GM-CSF is essential for CD4 T cell survival in vivo
###end title 28
###begin p 29
###xml 177 184 177 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 401 394 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 491 492 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 726 729 726 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 742 750 742 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 854 857 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 917 925 917 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">Mice</span>
###xml 402 405 <span type="species:ncbi:31658">CFA</span>
To confirm the importance of GM-CSF in T cell proliferation in vivo, we performed four-way adoptive transfer experiments by injection of GM-CSF-deficient or GM-CSF-competent OVA323-339 specific CD4+ T cells (from DO11.10 mice) into GM-CSF-/- and WT mice. CD4+ T cells were labeled with CFSE prior to injection to monitor cell cycling and in vivo tracking. Mice were immunized 1 d later with OVA323-339/CFA, and DO11.10 T cells were monitored longitudinally in the blood. GM-CSF-competent CD4+ T cells expanded considerably in immunized WT hosts until day 7 before they started to collapse. Expansion and collapse of GM-CSF-deficient CD4+ T cells was unaltered in WT hosts. In contrast, no such expansion was observed in GM-CSF-/- recipients (Fig. 5 A). Consistently, a significantly reduced number of DO11.10 T cells was observed in draining LN of GM-CSF-/- compared with WT hosts at days 3 and 5 after immunization (Fig. 5 B).
###end p 29
###begin p 30
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GM-CSF prevents apoptosis of specific T cells.</bold>
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 115 118 115 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 207 208 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 277 284 276 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 320 321 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 389 390 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 420 421 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 426 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 515 516 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 604 607 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 610 611 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 620 623 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 658 661 655 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 665 666 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 675 678 670 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 685 686 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 720 721 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 725 726 720 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 847 848 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 852 853 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1005 1006 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1009 1010 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1018 1019 1013 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1072 1075 1067 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1106 1109 1101 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1127 1130 1122 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1142 1143 1137 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1180 1187 1175 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 1239 1240 1234 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1243 1244 1238 1239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1252 1253 1247 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
###xml 236 240 <span type="species:ncbi:10090">Mice</span>
###xml 296 299 <span type="species:ncbi:31658">CFA</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 469 472 <span type="species:ncbi:31658">CFA</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 1076 1080 <span type="species:ncbi:10090">mice</span>
###xml 1188 1191 <span type="species:ncbi:31658">CFA</span>
###xml 1321 1325 <span type="species:ncbi:10090">mice</span>
GM-CSF prevents apoptosis of specific T cells. CD4+ T cells were purified from DO11.10/GM-CSF+/+ and DO11.10/GM-CSF-/-mice and labeled with CFSE before intravenous injection into WT or GM-CSF-/- mice (5 x 106 cells per mouse) at day 3. Mice were immunized s.c. with 200 mug OVA323-339 peptide in CFA at day 0. (A) KJ1-26+ CD4 T cell expansion was monitored over 10 d in the blood of mice (n = 4). The frequency of KJ1-26+ CD4+ T cells in control animals immunized with CFA only was <0.5%. (B) Total number of KJ1-26+ cells in draining LN at days 3 and 5 after immunization. Filled columns, DO11.10/GM-CSF+/+CD4+-->GM-CSF+/+ mice; open columns, DO11.10/GM-CSF-/- CD4+-->GM-CSF-/- mice (n = 3). (C) Proliferation of KJ1-26+ CD4+ T cells is shown by CFSE dilution at days 3 (left) and 5 (right). (D) Annexin V (top) and PI (bottom) staining of KJ1-26+ CD4+ T cells in draining LN at days 3 and day 5. (E) Shown is the number of cell division determined by CFSE dilution and percentage of apoptotic (Annexin V+ PI-) KJ1-26+ cells at day 3 after immunization. (F) WT and GM-CSF-/- mice were injected with GM-CSF-/-/DO11.10 or GM-CSF+/+/DO11.10 CD4+ T cells before immunization with OVA323-339/CFA. Shown is the frequency of apoptotic (Annexin V+ PI-) KJ1-26+ cells at day 3 after immunization. Error bars indicate SD of three mice per group. One representative experiment of two is shown. * , P < 0.05; ** , P < 0.01.
###end p 30
###begin p 31
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 194 202 194 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 596 599 596 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 636 644 636 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 700 703 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 724 732 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 887 888 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 891 892 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 979 982 979 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1057 1060 1057 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1088 1096 1088 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 1155 1163 1155 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1199 1202 1199 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1290 1298 1290 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 479 482 <span type="species:ncbi:31658">CFA</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
To determine whether GM-CSF promoted cell expansion by enhancing the rate of cell division, we measured CFSE dilution (35). Surprisingly, we found that cell cycling was not dependent on GM-CSF (Fig. 5 C). Therefore, we hypothesized that reduced CD4 T cell numbers in the absence of GM-CSF resulted from enhanced cell death. To test this, we measured apoptosis and cell death by staining transgenic CD4+ T cells from draining LN with Annexin-V and propidium iodide (PI) after OVA/CFA immunization. Indeed, we found threefold- and twofold-increased numbers of Annexin-V transgenic T cells in GM-CSF-/- mice at days 3 and 5, respectively (Fig. 5 D). Similarly, PI-positive cells were increased in GM-CSF-/- mice at these days (Fig. 5 D). By gating on cells that had undergone the same number of cycles as measured by CFSE dilution, we found that the percentage of apoptotic cells (Annexin-V+ PI-) increased with the division number and that this increase was much stronger in GM-CSF-/- mice. After five cell divisions, the number of apoptotic T cells in GM-CSF-/- mice was threefold higher (Fig. 5 E). As expected from the results in the previous paragraph (Fig. 5 A), apoptosis was increased in GM-CSF-/- recipients irrespective of the ability of transferred T cell to produce GM-CSF or not (Fig. 5 F). These results demonstrate that GM-CSF produced by non-T cells sustains survival of antigen-specific T cells in vivo.
###end p 31
###begin title 32
GM-CSF sustains IL-6-mediated T cell survival
###end title 32
###begin p 33
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 272 273 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 349 334 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 760 768 753 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 774 789 767 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 925 933 918 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 1322 1330 1315 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1357 1365 1350 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 1438 1446 1428 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 E</xref>
It has been reported that GM-CSF receptor is not expressed by resting and activated splenic T cells (36). Indeed, using sensitive quantitative RT-PCR, we could not detect expression of GM-CSFR-alpha and the signal transducing beta subunit (AIC2B) by naive or activated CD4+ T cells differentiated in Th1, Th2, or Th17 polarizing conditions (Fig. 6 A). In contrast, primary splenic DC expressed both GM-CSFR subunits. This result suggests that GM-CSF does not act on the expanding T cells directly but mediates T cell survival indirectly, possibly by stimulating production of T cell growth/survival factors in GM-CSF-responsive cells such as DC and macrophages. We showed that exogenous and endogenous GM-CSF enhanced IL-6 production by DC and/or macrophages (Fig. 2 B; and Fig. 3, A and B). Consistently, we found that endogenous GM-CSF was critically required for antigen-dependent IL-6 production in T cell/DC cocultures (Fig. 6 B). Neutralization of endogenously produced IL-6 by mAb reduced proliferation in WT cocultures, although not to values seen in GM-CSF-deficient cultures (Fig. S1, available at ). These data suggest that GM-CSF regulates CD4 T cell expansion, at least partially, through induction of IL-6. Indeed, supplementation of GM-CSF-deficient cocultures with IL-6 reconstituted T cell proliferation (Fig. 6 C) and inhibited apoptosis (Fig. 6 D), whereas rIL-2 or rIL-1beta showed a small or no effect, respectively (Fig. 6 E).
###end p 33
###begin p 34
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T cell survival is mediated by DC-secreted factors and IL-6.</bold>
###xml 210 211 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 215 216 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 251 252 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 372 373 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 405 408 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 418 421 408 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 458 459 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 487 490 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 508 511 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 575 583 565 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339.</sub>
###xml 692 693 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 806 809 796 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 819 822 809 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 856 863 845 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 953 954 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1039 1040 1028 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1078 1079 1067 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1081 1082 1070 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1103 1104 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1106 1107 1095 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1128 1129 1117 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1132 1133 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1243 1244 1232 1233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1373 1374 1362 1363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1411 1414 1400 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1432 1435 1421 1424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1471 1474 1460 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1484 1487 1473 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1672 1679 1660 1667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 1827 1828 1815 1816 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
###xml 1436 1440 <span type="species:ncbi:10090">mice</span>
###xml 1488 1492 <span type="species:ncbi:10090">mice</span>
###xml 1539 1543 <span type="species:ncbi:10090">mice</span>
###xml 1636 1640 <span type="species:ncbi:10090">mice</span>
###xml 1702 1705 <span type="species:ncbi:31658">CFA</span>
###xml 1849 1853 <span type="species:ncbi:10090">mice</span>
T cell survival is mediated by DC-secreted factors and IL-6. (A) Expression of GM-CSFR-alpha, GM-CSFR-beta (AIC2B), and IL-2Rbeta was determined by quantitative RT-PCR using cDNA of cells indicated. Naive CD62L+ CD4+ T cells (lane 1) and splenic CD11c+ DC (lane 5) were purified by flow cytometry (purity > 98%). Th1 (lane 2), Th2 (lane 3), and Th17 (lane 4) polarized CD4+ T cells. (B and C) DC of GM-CSF-/- or GM-CSF+/+ mice were cultured with purified CD4+ T cells from DO11.10/GM-CSF-/- or DO11.10/GM-CSF+/+ mice, respectively, in the presence of titrating amounts of OVA323-339. (B) IL-6 levels in the culture supernatant at day 3 were determined by ELISA. (C) Proliferation measured by 3H-Thymidine incorporation in the absence and in the presence of 20 ng/ml rIL-6. (D) Splenocytes of DO11.10/GM-CSF+/+ or GM-CSF-/- mice were cultured with 1 muM OVA323-339 in the absence and presence of 20ng/ml rIL-6 for 3 d before staining of cells with KJ1-26+ mAb, Annexin V (AV), and PI and analysis by flow cytometry. Dot plot gated on KJ1-26+ cells shows early apoptotic cells (PI-AV+), late apoptotic (PI+AV+), and dead cells (PI+ AV-). (E) GM-CSF-deficient cultures were supplemented with rIL-1, rIL-2, or rIL-6. Proliferation was measured by 3H-Thymidine incorporation after 3 d of culture. Proliferation index was calculated as described in Materials and methods. (F) CD4+ T cells purified from DO11.10/GM-CSF+/+ or DO11.10/GM-CSF-/- mice were injected i.v. into GM-CSF+/+ or GM-CSF-/- mice, respectively. 2 d later, groups of KO and WT mice were implanted with osmotic minipumps containing hIL-6 or were sham operated. Subsequently, mice were immunized with 200 mug OVA323-339 peptide emulsified in CFA. After 7 d, draining LN and spleen cells were analyzed by flow cytometry. Symbols indicate total number of splenic KJ1-26+ cells of individual mice. Horizontal lines indicate averages of groups. Shown is one representative experiment of three performed. *, < 0.05. Error bars indicate SD.
###end p 34
###begin p 35
###xml 400 401 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 F</xref>
###xml 464 465 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 498 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 576 579 576 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 790 791 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
We next studied whether IL-6 supplementation can restore CD4 T cell expansion in GM-CSF-deficient mice in vivo. IL-6 has a fast clearance kinetic in the blood, and periodic IL-6 injection is therefore not suitable to compensate continuous endogenous release (unpublished data). To ensure a continuous supply, we implanted osmotic minipumps containing IL-6 in mice after injection of naive DO11.10 CD4+ T cells. As shown in Fig. 6 F, the total number of DO11.10 CD4+ T cells was reduced in GM-CSF-/- mice compared with WT mice 7 d after immunization. Delivery of IL-6 to GM-CSF-/- mice increased the expansion of DO11.10 T cells. A similar reconstitution was also seen in the blood and LN (unpublished data). Collectively, these data indicate that GM-CSF prevents apoptosis and maintains CD4+ T cell responses, at least partially, by stimulation of IL-6 production in vivo.
###end p 35
###begin title 36
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
IL-17-producing cells CD4 T cells are reduced in GM-CSF-/- mice
###end title 36
###begin p 37
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 234 237 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 294 297 294 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 316 319 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 387 394 387 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 446 447 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 495 496 487 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 501 502 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 518 519 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 528 529 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 564 565 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 614 615 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 624 625 608 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 725 728 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 735 743 719 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 395 398 <span type="species:ncbi:31658">CFA</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 860 863 <span type="species:ncbi:31658">CFA</span>
IL-6 and IL-23 are key factors for development, maintenance, and pathogenicity of IL-17-producing CD4+ T (Th17) cells. Considering the defect of GM-CSF-/- CD4+ T cells in producing IL-17 in vitro, we studied Th17 development in GM-CSF-/- mice in vivo. To this end, we transferred DO11.10/GM-CSF-/- and DO11.10/GM-CSF+/+ CD4+ T cells to KO and WT mice, respectively. Immunization with OVA323-339/CFA resulted in a high frequency of IL-17+IFN-gamma- (Th17) cells and lower frequencies of IFN-gamma+IL-17- (Th1) and IL-17+IFN-gamma+ coproducers among OVA-specific CD4+ T cells in GM-CSF-competent mice. Th17 and IL-17+IFN-gamma+ CD4 populations were strikingly reduced, whereas frequencies of Th1 cells were unaffected in GM-CSF-/- mice (Fig. 7 B). Thus, GM-CSF was critical for development and survival of IL-17-producing cells upon immunization with antigen in CFA in vivo.
###end p 37
###begin p 38
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 58 59 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 69 70 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 79 80 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 84 85 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 105 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GM-CSF<sup>&#8722;</sup>/&#8722; mice show reduced frequencies of IL-17<sup>+</sup>IFN-&#947;<sup>&#8722;</sup> and IL-17<sup>+</sup>IFN-&#947;<sup>+</sup> CD4<sup>+</sup> T cell populations.</bold>
###xml 113 114 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 151 154 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 172 175 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 218 221 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 231 234 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 297 304 288 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 417 418 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 422 423 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 628 631 615 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 642 645 629 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 680 687 663 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 795 796 774 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 870 871 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 910 911 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 973 980 946 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 327 330 <span type="species:ncbi:31658">CFA</span>
###xml 332 336 <span type="species:ncbi:10090">Mice</span>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
###xml 688 691 <span type="species:ncbi:31658">CFA</span>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
GM-CSF-/- mice show reduced frequencies of IL-17+IFN-gamma- and IL-17+IFN-gamma+ CD4+ T cell populations. (A) CD4+ T cells purified from DO11.10/GM-CSF+/+ or DO11.10/GM-CSF-/- mice were adoptively transferred to GM-CSF+/+ or GM-CSF-/- mice, respectively, 2 d prior to immunization with 200 mug OVA323-339 peptide emulsified in CFA. Mice were boosted at day 7 and draining LN were removed at day 14 to determine KJ1-26+ CD4+ T cells producing IL-17 or IFN-gamma by flow cytometry. Top shows dot plots of a representative mouse per group. Bottom shows the frequency of cytokine-producing cells in individual mice. (B and C) GM-CSF-/- and GM-CSF+/+ mice were immunized with myhcalpha614-629/CFA at days 0 and 7. (B) IL-17 and IFN-gamma expression was determined by real-time PCR using cDNA from CD4+ T cells purified from draining LN at day 8. Values show means of groups (n = 3) of mice +/-SD. (C) At day 14, CD4+ T cells were isolated from LN and restimulated with myhcalpha614-629 as described in Materials and methods. IFN-gamma- and IL-17-producing cells were determined by ELISPOT analysis. Values indicate individual mice and means of groups.
###end p 38
###begin p 39
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 184 191 184 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">il17</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ifng</italic>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 314 317 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 333 341 333 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 440 441 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 462 455 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 486 494 482 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 652 660 644 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 769 770 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 192 195 <span type="species:ncbi:31658">CFA</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
Finally, we determined the role of GM-CSF in development of IL-17-producing CD4+ T cells in autoimmune myocarditis. GM-CSF-/- and control mice were immunized at days 0 and 7 with myhca614-629/CFA. Real time PCR analysis showed reduced il17 but normal ifng gene expression in purified CD4+ T cells from LN of GM-CSF-/- mice at day 8 (Fig. 7 B). At day 14, however, we found strongly reduced numbers of both IL-17- and IFN-gamma-producing CD4+ T cells in GM-CSF-/- mice by ELISPOT assay (Fig. 7 C). It is tempting to speculate that a majority of IFN-gamma-positive cells coproduce IL-17, as indicated by flowcytometry results of T cell transfer studies (Fig. 7 A). These data indicate that GM-CSF is critical for induction of IL-17 rather than IFN-gamma production by CD4+ T cells, but it later becomes essential for survival of both IL-17- and IFN-gamma-producing cells in autoimmune disease.
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin p 41
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 320 327 316 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 433 436 429 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 443 445 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 446 448 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 450 452 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 795 798 791 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 805 807 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 852 855 848 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 919 922 915 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 964 967 960 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1217 1220 1213 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1459 1462 1447 1450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1531 1532 1519 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1534 1536 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1544 1546 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1547 1549 1535 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1563 1565 1551 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1566 1568 1554 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 1584 1586 1572 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1587 1589 1575 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 1787 1789 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1817 1819 1801 1803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1821 1823 1805 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 1956 1957 1940 1941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1959 1961 1943 1945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 2079 2081 2063 2065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 2150 2151 2134 2135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2179 2182 2163 2166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
###xml 856 860 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
###xml 969 973 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1439 1442 <span type="species:ncbi:31658">CFA</span>
###xml 1463 1467 <span type="species:ncbi:10090">mice</span>
###xml 2183 2187 <span type="species:ncbi:10090">mice</span>
In this manuscript, we provide data suggesting that GM-CSF is essential for development of autoimmune myocarditis by promoting IL-6-dependent IL-17 production and survival of autoimmune CD4+ T cells. GM-CSF-/- mice were almost completely protected from myocarditis induced by immunization of heart autoantigen (myhcalpha614-629), which is in agreement with other publications reporting reduced EAE, arthritis, and gastritis in GM-CSF-/- mice (22-24, 37) and suggests that GM-CSF plays a key role in development of organ-related autoimmunity similar to IL-1, IL-6, and IL-23. Although activated DC are among the main producers of the latter proinflammatory cytokines, DC do not produce GM-CSF. Consistently, injection of TLR- and CD40-activated BM-DC from WT mice, which can restore EAM in IL-1R1-/- mice (26), failed to restore full-blown EAM in GM-CSF-/- mice. Nevertheless, injection of activated DC from WT or GM-CSF-/- mice increased disease severity in GM-CSF-/-, mice although not to levels observed in WT mice. These data suggest that GM-CSF produced by other cells is important for DC activation in addition to TLR and CD40 stimulation. Consistently, we found that stimulation of splenic DC from WT and GM-CSF-/- mice with rGM-CSF substantially increased TLR-induced production of the proinflammatory cytokines IL-6, IL-23, and TNF-alpha. Moreover, we showed that IL-6 and IL-23 production by DC was strongly impaired in myhcalpha/CFA-immunized GM-CSF-/- mice. Both IL-6 and IL-23 are essential for the development of EAM (5, 25), EAE (38-41), arthritis (42-44), and colitis (45-48), demonstrating the importance of these two cytokines for development of organ-related autoimmune and inflammatory diseases. Although some of these studies showed reduced CD4 T cell proliferation (25) and IFN-gamma production (39, 49) in the absence of IL-6, it is now thought that IL-6 mediates autoimmune disease by promoting development of pathogenic Th17 cells (9, 11). However, in addition to Th17 development, IL-6 has been shown to prevent apoptosis of effector and memory T cells (50). Similarly, we found that reduced expansion of antigen-specific CD4+ T cells in immunized GM-CSF-/- mice was caused by enhanced apoptosis and not a defect in T cell activation or cell division rate.
###end p 41
###begin p 42
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 253 256 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 396 399 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 403 404 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 496 499 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 820 823 820 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1117 1120 1117 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 824 828 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
It has been shown previously that a soluble factor secreted by activated DC was able to restore impaired proliferation of CD4+ T cells from GM-CSF-/- mice in vitro (51). We have identified that this factor is IL-6. Delivery of recombinant IL-6 to GM-CSF-/- mice in osmotic minipumps or to APC-T cell cocultures in vitro restored proliferation by inhibition of apoptosis of antigen-specific GM-CSF-/- CD4+ T cells. It should be noted that we failed to reconstitute autoimmune myocarditis in GM-CSF-/- mice and recovery of Th17 cells was achieved partially with variable results by implantation of IL-6-secreting osmotic minipumps or by infection with recombinant adenovirus expressing IL-6 (mAd5-IL6; reference 52). However, these approaches also failed to reconstitute Th17 development and autoimmune myocarditis in IL-6-/- mice (unpublished data), indicating that local availability, concentration, and/or half-life of exogenous and ectopically produced IL-6 are not sufficient to reconstitute endogenous IL-6 levels required for disease development. In addition, restoration of Th17 cells and autoimmunity in GM-CSF-/- mice may require supplementation of both IL-6 and IL-23, as indicated by our results.
###end p 42
###begin p 43
###xml 217 220 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 417 426 417 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Figs. 4 B</xref>
###xml 431 434 431 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">6 C</xref>
###xml 494 495 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 602 603 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 613 621 613 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 724 731 720 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 814 815 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 960 967 956 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Figs. 2</xref>
###xml 972 973 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4</xref>
###xml 1024 1025 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1215 1218 1211 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1221 1222 1217 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1285 1287 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 732 735 <span type="species:ncbi:31658">CFA</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
###xml 1056 1060 <span type="species:ncbi:10090">mice</span>
Although we cannot exclude that other antiapoptotic cytokines stimulated by GM-CSF show a similar effect than IL-6 for T cell survival, we have shown that addition of IL-1 or IL-2 could not restore expansion of GM-CSF-/- CD4+ T cells. Although GM-CSF production by activated T cells can contribute to T cell proliferation in vitro, particularly when no other GM-CSF-producing cell is present in the microenvironment (Figs. 4 B and 6 C), our in vivo adoptive transfer experiments with TCR tg CD4+ T cells demonstrate that GM-CSF production by non-T cells is critical for survival of antigen-specific CD4+ T cells (Fig. 5 F). Indeed, we found that a gemisch of Macrophages and DC isolated from WT mice at day 7 after myhcalpha614-629/CFA immunization produced GM-CSF (unpublished data). Interestingly, although CD11c+ DC isolated from naive WT BALB/c mice and BM-DC did not produce GM-CSF upon TLR stimulation (i.e., CpG, LPS) or in cocultures with CD4 T cells (Figs. 2 and 4), we could measure GM-CSF in supernatants of CD11c+ cells purified from immunized mice, although less than in the gemisch of macrophages and DC (not depicted). It is tempting to speculate that blood circulating inflammatory monocytes (CX3CR1lowGr1+), which differentiate into functional DC in inflamed tissues (53), have the ability to produce GM-CSF.
###end p 43
###begin p 44
###xml 358 373 358 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 379 390 379 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A&#8211;C</xref>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 493 508 493 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, E and F</xref>
###xml 315 318 <span type="species:ncbi:31658">CFA</span>
The absence of GM-CSF receptor on naive and effector CD4 T cell subsets excludes direct regulation of Th17 lineage commitment by GM-CSF. Consistently, addition of GM-CSF to DC/CD4 T cell cocultures did not induce Th17 differentiation in vitro. However, stimulation of DC with microbial ligands or immunization with CFA adjuvants promoted DC IL-6 production (Fig. 2, B and C; and Fig. 3, A-C), resulting in GM-CSF production by activated CD4+ T cells, which was required for Th17 polarization (Fig. 4, E and F). Requirement of GM-CSF for Th17 development was overcome in the presence of TGFbeta/IL-6 or TGFbeta/IL-21, further indicating that GM-CSF acts indirectly by enhancing production of Th17-polarizing cytokines.
###end p 44
###begin p 45
###xml 208 211 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 336 339 332 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 369 376 361 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 414 415 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 420 421 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 458 461 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 590 591 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 596 597 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 699 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 704 705 684 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 719 720 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 725 726 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 755 762 727 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 869 870 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 875 876 839 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1037 1038 997 998 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1175 1182 1135 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 1195 1196 1155 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1238 1239 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1270 1277 1226 1233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 377 380 <span type="species:ncbi:31658">CFA</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 547 550 <span type="species:ncbi:31658">CFA</span>
Consistent with a key role of IL-6 and IL-23 in generation and maintenance of Th17 cells, we found that impaired IL-6 and IL-23 production was associated with reduced numbers of Th17 cells in immunized GM-CSF-/- mice in vivo. Interestingly, numbers of IFN-gamma-producing cells determined by ELISPOT were also strongly reduced in GM-CSF-/- mice immunized with myhcalpha614-629/CFA, whereas development of IFN-gamma+IL-17- (Th1) cells was unaffected in GM-CSF-/- mice after adoptive transfer of DO11.10 transgenic T cells and immunization with OVA/CFA. In contrast, a population of IFN-gamma+IL-17+ double producers was also reduced in this setting. Unfortunately, we could not distinguish IFN-gamma+IL-17- and IFN-gamma+IL-17+ cells specific for myhcalpha614-629 by ELISPOT, and it is possible that the majority of IFN-gamma-producing cells actually represent IFN-gamma+IL-17+ double producers. The dynamics of IL-17 and IFN-gamma production during differentiation of distinct subpopulations depends on the number of antigen-specific CD4+ T cells and the strengths of TCR stimulation (unpublished data), which may also explain possible differences in adoptive transfer of OVA323-339-specific CD4+ T cells and development of endogenous CD4+ T cells specific for myhcalpha614-629.
###end p 45
###begin p 46
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 219 224 219 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35-55</sub>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 375 378 375 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 455 458 455 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
The balance of Th17 and Treg cells is key for development of autoimmunity. Development of Foxp3+ Treg cells is enhanced at the expense of Th17 cells in IL-6-deficient mice immunized with the encephalitogenic peptide MOG35-55, which prevents development of EAE (54). It is important to note that we did not find significant differences in Foxp3+ Treg cells in immunized GM-CSF-/- mice (Fig. S2, available at ), which may indicate that IL-6 levels in GM-CSF-/- mice are sufficient to balance development of Treg cells. However, it remains to be shown whether Treg number and function are similar in autoimmune myocarditis and EAE and the different genetic backgrounds (BALB/c vs C57BL/6).
###end p 46
###begin p 47
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">57</xref>
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 586 587 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 438 442 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
Our results do not exclude a role for GM-CSF in the effector phase of the response. Elegant studies have demonstrated previously that GM-CSF production by encephalitogenic T cells is required for the development of EAE, probably by activation of microglial cells (23, 55, 56). Similarly, GM-CSF produced by myosin-specific effector CD4+ T cells may activate heart-resident macrophages. Indeed, GM-CSF mRNA is up-regulated in the heart of rats with autoimmune myocarditis (57), and we found that a high frequency of CD4+ T cells activated in vitro under Th17-polarizing conditions or CD4+ T cells isolated from the CNS of mice with EAE coexpress GM-CSF and IL-17 (unpublished data), demonstrating that GM-CSF is an effector cytokine of Th17 cells.
###end p 47
###begin p 48
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 346 340 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
In summary, our studies demonstrate a previously unrecognized role of GM-CSF in survival of Th17 cells that mediate autoimmunity. GM-CSF regulates autoantigen-specific CD4+ T cells indirectly through stimulation of IL-6 and IL-23 production by DC and macrophages in the presence of microbial products, as illustrated in the scheme shown in Fig. 8. Our results may have important implications for understanding the mechanisms of cancer and other immunotherapies using GM-CSF as potent adjuvant.
###end p 48
###begin p 49
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model for GM-CSF&#8211;mediated autoimmunity.</bold>
###xml 90 93 <span type="species:ncbi:31658">CFA</span>
Model for GM-CSF-mediated autoimmunity. PAMPs such as CpG and mycobacterial components in CFA induce DC activation/maturation and production of proinflammatory cytokines, including IL-6, which promote activation of naive CD4 T cells (Thp) and secretion of GM-CSF, IFN-gamma, and IL-17. Macrophages (and possibly subpopulations of DC) can produce GM-CSF directly upon encounter of PAMPs. GM-CSF further enhances IL-6 and IL-23 production by DC and macrophages. IL-6 acts at two levels on activated T cells. It enhances survival (both Th1 and Th17) and, together with TGF-beta, drives RORgammat expression to allow further Th17 polarization. IL-23 can promote Th17 cell maintenance and/or pathogenicity. Blue and red arrows indicate secretion of and stimulation of, respectively.
###end p 49
###begin title 50
MATERIALS AND METHODS
###end title 50
###begin title 51
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 51
###begin p 52
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 266 269 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">Mice</span>
GM-CSF-/- mice (provided by A. Dunn, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia) (21) were backcrossed to BALB/c for seven generations. DO11.10 transgenic GM-CSF-/- mice were obtained by crossing DO11.10 mice (58) with GM-CSF-/- mice. BALB/c WT controls were purchased from Charles River Laboratories. Mice were maintained in isolated ventilated cages in an animal facility free of specific pathogens (BioSupport) and were used for experiments at the age of 8-12 wk. All animal experiments were performed in accordance with Swiss federal legislation and have been approved by the local overseeing body Gesundheitsdirektion Kanton Zurich, Veterinaeramt (permission 148/2005).
###end p 52
###begin title 53
Antibodies and cytokines.
###end title 53
###begin p 54
###xml 283 284 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 294 295 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Antibodies specific to CD11c, CD86, CD40, CD4, IL-12p40, TNF-alpha, IFN-gamma, IL-17, or Annexin V, conjugated with FITC, PE, or APC were purchased from eBioscience. Anti-KJ1.26 mAb (idiotype-specific DO11.10 TCR) was produced in house and conjugated with biotin. Purification of CD4+ and CD11c+ cells with magnetic beads (MACS; Miltenyi Biotec) was performed according to manufacturer instructions. Intracellular staining for cytokines was performed after fixation with 2% formaldehyde in the presence of 0.5% saponin. Recombinant GM-CSF (PeproTech), IL-1beta (provided by G. Spohn, Cytos biotechnology, Schlieren, Switzerland), and hIL-6 (provided by L. Aarden, University of Amsterdam, Amsterdam, Netherlands) were used at concentrations indicated in the text.
###end p 54
###begin title 55
Induction of EAM.
###end title 55
###begin p 56
###xml 85 92 84 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
###xml 140 143 <span type="species:ncbi:31658">CFA</span>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
###xml 335 339 <span type="species:ncbi:10090">Mice</span>
Mice were injected s.c. with 100 mug per mouse of the mouse cardiac myhc peptide myhc614-629 Ac-RSLKLMATLFSTYASADR-OH (ANAWA) emulsified in CFA (1 mg/ml H37Ra; DIFCO) on days 0 and 7. At day 0, 400 ng per mouse of Pertussis Toxin (List Biological Laboratories, Inc.) dissolved in PBS containing 1% normal mouse serum was injected i.p. Mice were killed 21 d after the first injection.
###end p 56
###begin title 57
Histopathology.
###end title 57
###begin p 58
###xml 10 14 <span type="species:ncbi:10090">mice</span>
Immunized mice were killed and hearts were removed and fixed in 4% formalin (Sigma-Aldrich). Upon hemotoxylin and eosin staining, myocarditis was histologically scored using grades from 0 to 4 (0, no inflammatory infiltrates; 1, small foci of inflammatory cells between myocytes; 2, larger foci of >100 inflammatory cells; 3, >10% of a cross section involved; 4, >30% of a cross section involved).
###end p 58
###begin title 59
ELISA antibody measurement.
###end title 59
###begin p 60
###xml 18 25 18 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 234 241 233 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 478 479 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 568 573 567 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">405nm</sub>
###xml 426 431 <span type="species:ncbi:10090">mouse</span>
ELISA against myhc614-629 was performed as previously described (28). In brief, coating of MaxiSorp microtiter plates (Thermo Fisher Scientific) with 5 mug/ml streptavidin (Invitrogen) was followed by incubation with biotinylated myhc614-629 (ANAWA). Afterward, threefold serial dilutions of serum were incubated for 1 h at room temperature, followed by extensive washing and the addition of Alkaline-phosphatase-labeled anti-mouse IgG (SouthernBiotech). After development with p-nitrophenylphosphate (Sigma-Aldrich), antibody titers were determined at half maximal OD405nm.
###end p 60
###begin title 61
DC activation.
###end title 61
###begin p 62
###xml 329 330 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
Spleens of mice were digested for 1 h with collagenase and purified by MACS using anti-CD11c magnetic beads (Miltenyi Biotec). Afterward, DC were activated with the following different stimuli: 1 mug/ml LPS (Sigma-Aldrich) or titrating amounts of CpG (Microsynth). For surface staining, DC were incubated at 37degreesC with 5% CO2 for 12 h. Afterward, cells were blocked with anti-CD16/CD32 (eBioscience) and stained for activation markers. Cytokine ELISAs were performed on supernatants from DC culture stimulated for 24 h.
###end p 62
###begin title 63
Cytokine production.
###end title 63
###begin p 64
###xml 600 601 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
IL-6 and IL-12p70 levels were measured by ELISA. Microtiter plates (MaxiSorp) were coated with unlabeled capture anti-IL-6 or anti-IL-12p40 antibodies (eBioscience) at a concentration of 2 mug/ml for 12 h at 4degreesC. After blocking the plates with 1% BSA and washing, samples were incubated on the plates for 1 h. Detection was performed by incubating the plates with 1 mug/ml biotinylated anti-IL6 or anti-IL12p70 antibodies, respectively (eBioscience), followed by alkaline-phosphatase-labeled streptavidin (SouthernBiotech). Absorption at 405 nm was measured after incubation of the plates with p-nitrophenylphosphate.
###end p 64
###begin title 65
In vitro proliferation assay.
###end title 65
###begin p 66
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 416 423 416 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 714 715 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 851 858 848 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
Spleens of mice were digested for 1 h with collagenase and purified by MACS using anti-CD11c magnetic beads (Miltenyi Biotec), essentially as previously described (34). CD4+ T cells from DO11.10 tg GM-CSF-/- or GM-SF+/+ mice were isolated by MACS using anti-CD4 magnetic beads. 105 CD4+ T cells from tg mice were cultured with 2 x 104 DC or 105mitomycine C-inactivated splenocytes and titrating concentrations of OVA323-339 (EMC Microcollections) or ovalbumin protein (grade V; Sigma-Aldrich). In experiments indicated, cultures were supplemented with 20 ng/ml IL-1beta, IL-2 (1:500 dilution of a supernatant of a hybridoma producing hIL-2), and 20 ng/ml hIL-6. Proliferation was measured by pulsing cultures with 3H-Thymidine (Hartmann Analytic) for the last 12 h of a 3-d culture. Proliferation index was calculated by dividing the cpm at 200 nM OVA323-339 by cpm at baseline (without antigen).
###end p 66
###begin title 67
Antigen-specific Th1 and Th2 polarization in vitro.
###end title 67
###begin p 68
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 314 317 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 400 404 400 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 649 650 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 925 927 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
Spleens of mice were digested for 1 h with collagenase, and DC was isolated by an OptiPrep gradient (Axis-Shield), followed by sorting of CD11c+ cells on a FACS Vantage (BD Biosciences) to a purity >95%. For Th1 and Th2 polarization, naive CD4+ CD62Lhigh T cells from spleens of DO11.10/GM-CSF+/+ or DO11.10/GM-CSF-/- mice were isolated by MACS using anti-CD4 magnetic beads followed by sorting CD62Lhigh cells, using FACS Vantage, to a purity >98%. 104DC and 5 x 104 naive CD4+ T cells were cocultured in the presence of high (1 mM), intermediate (100 muM) or low (10 muM) concentrations of ovalbumin protein (grade V) for 3 d before addition of 104 DC and the same concentrations of antigen for another 2 d. T cell activation was assessed by staining with anti-CD25 mAb and CD62L mAb at day 3 of coculture. Th1/Th2 polarization was analyzed at day 5 by intracellular staining of IL-4 and IFN-gamma as previously described (34).
###end p 68
###begin title 69
Visualization of CD4 T cell expansion and subset differentiation in vivo.
###end title 69
###begin p 70
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 76 79 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 257 260 257 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 431 438 430 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 483 486 <span type="species:ncbi:31658">CFA</span>
T cells were isolated from the spleen of DO11.10 GM-CSF+/+ or DO11.10/GM-CSF-/- mice by sorting with anti-CD4 magnetic beads. After labeling of purified CD4+ T cells with CFSE (Invitrogen), 5 x 106 cells per mouse were injected intravenously in WT or GM-CSF-/- mice. One day later, mice were bled and cells stained with KJ1-26 mAb to confirm comparable number of transgenic T cells. Transferred mice were immunized with 200 mug OVA323-339 (ISQAVHAAHAEINEAGR; EMC Microcollection) in CFA (DIFCO). At days 3 and 5 after immunization, proliferation of T cells was analyzed by staining LN cells and FACS analysis.
###end p 70
###begin p 71
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
For induction of Th17 cells in vivo, mice were boosted at day 7. Draining LN were isolated at day 14 and cells were stimulated with 10-7 M PMA and 10-6 M Ionomycin for 5 h. Brefeldin A (Sigma-Aldrich) was added for the last 2 h of activation. Cytokine expression was detected by intracellular staining as described in the previous section.
###end p 71
###begin title 72
IL-6 supplementation by minipumps.
###end title 72
###begin p 73
###xml 85 88 85 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 359 366 356 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 381 384 <span type="species:ncbi:31658">CFA</span>
T cells were isolated from the spleen of DO11.10, purified, and transferred in GM-CSF+/+ or GM-CSF-/- mice as described in the previous section. After 1-2 d, osmotic minipumps (Alzet 2001; DURECT Corporation) were filled with 26 mug (3 mug/d delivery) rec hIL-6 and s.c. implanted in mice. Shortly after implantation, mice were immunized s.c. with 200 mug OVA323-339 emulsified in CFA.
###end p 73
###begin title 74
Quantitative PCR.
###end title 74
###begin p 75
Cells used to quantify cytokine receptors were FACS sorted (FACS Aria; Becton Dickinson). All cell populations were >99% pure. After in vitro culture in polarizing conditions for 3 d, cDNA was extracted with Tri-reagent (Molecular Research Center) according to the manufacturer's instructions. Quantitative PCR was performed on an iCycler (Bio-Rad Laboratories) according to the manufacturer's instructions. Oligonucleotides used for PCR amplification of cytokines and receptors were the following: GM-CSFR-alpha forward, ACGTCATGCACCGTGACC; GM-CSFR-alpha reverse, CATTGACATCCAGCGTGA; AIC2B forward, ACCAGCAAATGGCACTCAC; AIC2B reverse, GCTGGTGATAGAGGGTCATGT; CD122 forward, GAAGAGGCTCTGAATGTCACAA; CD122 reverse, ACGACCCGAGGATCAGGTT; IL17 forward, GCAAAAGTGAGCTCCAGAAGG; IL17 reverse, AGCTTCCCAGATCACAGAGG; IFN-gamma forward, GCTCTGAGACAATGAACGCTAC; and IFN-gamma reverse, TTC TAG GCTTTCAATGACTGTGC.
###end p 75
###begin title 76
ELISPOT.
###end title 76
###begin p 77
###xml 322 323 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 367 374 353 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">614-629</sub>
###xml 425 426 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 468 469 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 482 483 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 586 587 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 608 609 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 642 644 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 1542 1543 1515 1516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1403 1407 <span type="species:ncbi:10090">mice</span>
Filter plates (96-well; Multi-Screen-IP; Millipore) were coated overnight at 4degreesC with 2 mug/well of affinity chromatography-purified anti-IFN-gamma (mAB AN18,) or with 0.1 mug/well of anti-IL-17 (BD Biosciences) in PBS. Plates were washed twice with PBS and blocked with IMDM/10% FCS for 2 h at RT (200 mul/well). 106/ml BALB/c BM-DC was pulsed with 10 mug myhc614-629/ml for 15 min on ice. DC were adjusted to 0.4 x 106/ml, and 20,000 cells were used as APC. 105 purified CD4+ T cells were incubated 6 h together with peptide-pulsed or unpulsed APCs at 37degreesC. Setups with 105 T cells only and CD4+ T cells stimulated with 2.5 x 10-7 M PMA and 1.25 mug/ml ionomycin (Sigma-Aldrich) served as controls. Plates were washed five times with PBS, and 2 mug/ml anti-IFN-gamma-biotin (mAb XMGD6) or 2 mug/ml anti-IL-17 (BD Biosciences) were added to the respective plate and incubated for 1 h at room temperature. Plates were washed five times with PBS and incubated for 1 h with streptavidin-alkaline-phosphatase (1:1,000 in PBS; Dianova). After five further washing steps, the spots were visualized by using the BCIP/NBT (5-bromo-4-chloro-3-indol-phosphate-toluidine/nitroblue-tetrazoliumchloride) Plus substrate (Mabtech). The enzymatic reaction was stopped by rinsing the wells with water. Plates were counted with an ELISPOT Reader (Autoimmun Diagnostika GmbH). ELISPOT responses of individual mice are expressed as mean number of specific spot-forming cells (experimental sample, negative control with unpulsed APCs) per 100,000 CD4+ T cells from triplicate measurements.
###end p 77
###begin title 78
Statistical analysis.
###end title 78
###begin p 79
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 306 314 306 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
Statistical analysis was performed with the help of Prism (GraphPad Software, Inc.). Two-tailed unpaired Student's t test with a confidence interval of 95% was performed for normal distributed data. Histological scores were analyzed with two-tailed Mann-Whitney test. Results obtained by flow cytometry in Fig. 7 A were evaluated using Kolmogorov-Smirnov statistical analysis for comparisons between frequency distributions. If not mentioned otherwise, error bars indicate SD. P < 0.05 was considered to be significant.
###end p 79
###begin title 80
Online supplemental material.
###end title 80
###begin p 81
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows that neutralization of IL-6 by mAb inhibits antigen-specific CD4+ T cell proliferation. Fig. S2 shows that frequencies of Foxp3+ Treg cells are comparable in GM-CSF-/- and GM-CSF+/+ mice. Online supplemental material is available at .
###end p 81
###begin title 82
Supplementary Material
###end title 82
###begin title 83
[Supplemental Material Index]
###end title 83
###begin p 84
This project has been supported by a grant from the Swiss National Foundation (No. 3100A0-100233/1).
###end p 84
###begin p 85
The authors have no conflicting financial interest.
###end p 85

